Prof. Yohei Yamauchi of ETH Zurich and TAGCyx Announces a Research Collaboration for the discovery of a novel Xenoligo® aptamer in the field of infectious diseases field.

March 13th, 2024
Prof. Yohei Yamauchi at ETH Zurich
TAGCyx biotechnologies Inc.

Prof. Yohei Yamauchi. Professor of Molecular Medicine at the Institute of Pharmaceutical Sciences (IPW) at ETH Zurich, Zurich, and TAGCyx biotechnologies Inc., Tokyo, announced entering into a research collaboration for the discovery of novel Xenoligo® aptamers in the field of infectious diseases field.

Prof. Yohei Yamauchi, MD PhD, is an expert in the area of virus-host interaction of zoonotic viruses such as influenza A virus and SARS-CoV-2. He is interested in the mechanism of how viruses take advantage of host cell processes and pathways to promote cell entry and establish infection to ultimately cause disease. Prof. Yamauchi aims to use this knowledge to inform new concepts for antivirals.

TAGCyx has invented its proprietary artificial nucleic acid base-pair technology, Xenoligo® that enables to produce high avidity and selective functional DNA aptamers and is engaged in its own drug discovery business and drug discovery partnerships.

Both parties intend to collaborative research to discover and generate novel DNA aptamers for specific targets in the field of infectious diseases using TAGCyx‘s artificial base containing DNA aptamer discovery platform, Xenoligo®, and to evaluate the efficacy of the Xenoligo® aptamers in interfering with infectivity of viruses in Prof. Yamauchi team.

For further information, please contact:
Prof. Yohei Yamauchi Website
E-Mail: yohei.yamauchi@pharma.ethz.ch

TAGCyx biotechnologies Inc. Website
E-Mail: info@tagcyx.com